Caplin Point Laboratories has announced the outcomes of its Board of Directors meeting held on August 12, 2026. The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and recommended a final dividend of ₹4/- per equity share for the financial year ended March 31, 2026. Key leadership appointments were also approved.
Caplin Point Laboratories Board Meeting Outcomes
Caplin Point Laboratories Limited announced significant decisions following its Board of Directors meeting on August 12, 2026. The board reviewed and approved the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026, alongside the Limited Review Report. A press release and investor presentation detailing these results have also been released.
Dividend Recommendation and Record Date
A key highlight from the meeting was the recommendation of a final dividend of ₹4/- (200%) per equity share of ₹2/- each for the financial year ended March 31, 2026. This dividend, if approved by shareholders at the upcoming Annual General Meeting (AGM), is slated for payment on or before October 24, 2026. The board also approved the record date for determining shareholder eligibility for this dividend, which will be communicated separately.
Leadership Appointments
The company also announced the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director for a further period of two years, effective August 25, 2026, to August 24, 2028, subject to shareholder approval. Additionally, Mr. D. Muralidharan (DIN: 08301904) was appointed as a Whole-Time Director for a two-year term from August 12, 2026, to August 11, 2028. Mr. Muralidharan will continue in his role as Chief Financial Officer.
Annual General Meeting Scheduled
The 35th Annual General Meeting of the Company is scheduled to be convened on Friday, September 25, 2026, and will be conducted through Video Conferencing/Other Audio-Visual means.
The meeting commenced at 10:45 AM and concluded at 1:25 PM. Details regarding changes in Directors, as per SEBI Listing Regulations, are provided in Annexure 5.
Source: BSE
